Five-year STOPDAPT-2 ACS results (2986 patients after PCI), 1-year landmark: clopidogrel beat aspirin monotherapy on the cardiovascular and bleeding composite (6.18% vs 8.27%; HR 0.75). In the pooled 5991-patient cohort this was not significant (HR 0.86).
RCTn = 5,991
Watanabe et al. Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort